Engitix Therapeutics
Cherie Akpotor began their career in 2020 as a Laboratory Coordinator at Prenetics. In 2022, they joined Engitix Therapeutics as an Associate Scientist.
Cherie Akpotor attended the University of Leicester from 2016 to 2019, where they obtained a Bachelor of Science in Medical Biochemistry. Cherie then continued their studies at the same university from 2019 to 2020, obtaining a Master of Science in Cancer Cell and Molecular Biology.
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.